Clinical trial · Interventional
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
NCT00774332CI-TRIAL-00001737unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CODOX-M | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Duration of complete remission, disease-free survival, overall survival, toxicities
- timeFrame
- 2009
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with relapsed/resistant acute lymphoblastic leukemia * Patients must be between 15 and 65 years of age. * Estimated life expectancy of more than 3 months * ECOG performance status of 2 or lower, Karnofsky scale \> 60 (see appendix I) * Adequate cardiac function (EF\>45%) on echocardiogram or MUGA scan * Adequate kidney function (estimated Ccr \>50 ml/min) Exclusion Criteria: * Patients with CNS involvement of leukemic blasts will not be excluded. * Patients with extramedullary relapse(s) only will be excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.